HEALTHSTORY 590· JULY 26, 2026

FDA panel splits on peptide compounding, backing epitalon while rejecting emideltide

An FDA advisory panel voted Friday to allow compounding pharmacies to produce epitalon while narrowly recommending against the same permission for emideltide. Compounding pharmacies, for those unfamiliar with the term, are facilities…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 589Training AI models on workplace knowledge may hand employees an unexpected advantage NEXT STORY 591 →TSMC is speeding up its Arizona chip plants to meet AI demand, CFO says

Keep reading

More from the desk.

04HEALTH

U.S. agency commits $62.7 million to build FDA-authorized AI for heart failure care

A federal health research agency is committing $62.7 million to develop artificial intelligence systems designed to help manage heart failure, where heart failure means the heart muscle can no longer pump enough blood to meet the body's…

health2 MIN

58HEALTH

Readers debate doctor credentials, AI in the exam room, and surrogacy in STAT's First Opinion letters

When physician credentials, artificial intelligence in the exam room, and surrogacy generated enough reader mail to warrant a public reply, STAT published the letters. The health and life sciences publ

health1 MIN

79HEALTH

A drug for Angelman syndrome failed its final trial. Researchers say the science is not done.

A late-stage trial for an experimental Angelman syndrome drug came back negative this week, dealing a major blow to patients and to the company behind it. Late-stage, in clinical testing, means the final ro

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk